Cynata Therapeutics Treated First Patient with CYP-001

Cynata Therapeutics Treated First Patient with CYP-001

By, Admin 6 March 2024

Cynata Therapeutics announces first patient treated in phase 2 trial of CYP-001 in high-risk aGvHD
 

Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, confirms that the first patient has been enrolled and treated in its phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease (aGvHD).

CYP-001

  • CYP-001 is Cynata’s Cymerus off-the-shelf iPSC1 -derived MSC2 product candidate for intravenous infusion, which previously generated very encouraging safety and efficacy results in a phase 1 clinical trial in steroidresistant aGvHD.
  • The US FDA has cleared an Investigational New Drug (IND) application for CYP-001 and granted the product Orphan Drug Designation4 for the treatment of aGvHD.

About aGvHD

  • aGvHD is a potentially life-threatening complication of bone marrow transplants or similar procedures. 
  • It arises when immune cells in the transplant (the graft) attack the recipient’s tissues (the host) as “foreign”. 
  • In this trial, CYP-001 is being investigated as a potential immune modulating treatment for aGvHD.

Phase 2 Trial

  • This global phase 2 trial aims to enrol approximately 60 patients with high-risk aGvHD, who will be randomised to receive either steroids plus CYP-001, or steroids plus placebo. 
  • The trial has been approved to commence in Australia, the USA and Turkey, and numerous clinical centres across those jurisdictions are now open for recruitment. 
  • The first patient was enrolled in the USA.

Satement from CEO

Dr Kilian Kelly, Cynata’s chief executive officer, said: “The treatment of the first patient in this phase 2 trial marks a milestone moment in the clinical development journey of CYP-001 for aGVHD. We are continuing to open additional clinical centres, and we anticipate completion of enrolment by the end of this calendar year, with primary results available in the second half of 2025.”

About Cynata Therapeutics

Cynata Therapeutics Limited is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus, a proprietary therapeutic stem cell platform technology.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!